You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PEG-BCT-100

Showing 1 - 25 of 8,365
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer, Pediatric Solid Tumor, Pediatric AML Trial in Australia, United Kingdom (PEG- BCT-100)

Completed
  • Cancer
  • +3 more
  • PEG- BCT-100
  • Adelaide, Australia
  • +13 more
Sep 1, 2022

Hepatocellular Carcinoma Trial in Hong Kong (pegylated recombinant human arginase)

Completed
  • Hepatocellular Carcinoma
  • pegylated recombinant human arginase
  • Hong Kong, Hong Kong
    Prince of Wales Hospital, the Chinese University of Hong Kong
Aug 5, 2021

Melanoma, Prostate Adenocarcinoma Trial in San Diego, Santa Monica (PEG-BCT-100)

Completed
  • Melanoma
  • Prostate Adenocarcinoma
  • PEG-BCT-100
  • San Diego, California
  • +1 more
Apr 22, 2020

Colonoscopy Trial in Chendu (100 ml lactulose combined with 1 L PEG, 100 ml lactulose combined with 2 L PEG, 200 ml lactulose)

Completed
  • Colonoscopy
  • 100 ml lactulose combined with 1 L PEG
  • +3 more
  • Chendu, Sichuan, China
    west china fourth hospital of Sichuan university
Dec 29, 2022

Hepatitis B, Chronic Trial in Worldwide (VIR-2218, VIR-3434, PEG-IFNa)

Recruiting
  • Hepatitis B, Chronic
  • San Francisco, California
  • +39 more
Oct 3, 2022

Tumor, Colorectal Cancer Trial in United States (NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab)

Completed
Has Results
  • Tumor
  • Colorectal Cancer
  • NKTR-102 100 mg/m2
  • +2 more
  • Scottsdale, Arizona
  • +3 more
Jul 9, 2021

Breast Cancer Female Trial in Shanghai (MW05, PEG-rhG-CSF)

Completed
  • Breast Cancer Female
  • Shanghai, China
    Fudan University Affiliated Cancer Hospital
Dec 1, 2022

Lymphoma, Multiple Myeloma Trial in Chongqing (pegylated recombinant human granulocyte-colony stimulating factor)

Recruiting
  • Lymphoma
  • Multiple Myeloma
  • pegylated recombinant human granulocyte-colony stimulating factor
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Sep 23, 2023

Obesity, Overweight, Overweight and Obesity Trial in Chapel Hill (Core Behavioral Weight Loss (BWL) Intervention, Behavior

Not yet recruiting
  • Obesity
  • +2 more
  • Core Behavioral Weight Loss (BWL) Intervention
  • +7 more
  • Chapel Hill, North Carolina
    University of North Carolina at Chapel Hill
Nov 14, 2022

Polyethylene Glycols, Children, Only Trial (PEG 3350)

Not yet recruiting
  • Polyethylene Glycols
  • Children, Only
  • PEG 3350
  • (no location specified)
Jul 28, 2022

Dysphagia, QoL and Attitudes Towards PEG in ALS Patients

Not yet recruiting
  • Amyotrophic Lateral Sclerosis
  • Iowa Oral Performance Instrument (IOPI)
  • +3 more
  • Ljubljana, Slovenia
    University Medical Centre Ljubljana
Jul 1, 2022

Insufficient Physical Activity Trial in New York (5 Behavioral Change Techniques)

Recruiting
  • Insufficient Physical Activity
  • 5 Behavioral Change Techniques
  • New York, New York
    Institute of Health System Science
May 17, 2022

Sedentary Behavior Trial in New York (Behavioral Change Techniques)

Completed
  • Sedentary Behavior
  • Behavioral Change Techniques
  • New York, New York
    Center for Personalized Health
Jun 9, 2022

PegvisOMant and the Immune SystEm (PROMISE)

Active, not recruiting
  • Acromegaly
    • Rome, Italy
      Department of Experimental Medicine, "Sapienza" University of Ro
    Nov 6, 2022

    Acute Lymphoblastic Leukemia Trial in Memphis (Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia

    Completed
    Has Results
    • Acute Lymphoblastic Leukemia
    • Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
    • Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Jul 26, 2022

    Multiple Sclerosis, Chronic Progressive Trial in United States (NurOwn (MSC-NTF cells))

    Completed
    Has Results
    • Multiple Sclerosis, Chronic Progressive
    • NurOwn (MSC-NTF cells)
    • Los Angeles, California
    • +3 more
    Oct 20, 2022

    Drug/Agent Toxicity by Tissue/Organ, Leukemia Trial in Canada, Puerto Rico, United States (asparaginase, cyclophosphamide,

    Completed
    Has Results
    • Drug/Agent Toxicity by Tissue/Organ
    • Leukemia
    • Boston, Massachusetts
    • +9 more
    Nov 9, 2022

    Dedicated Breast CT for Diagnosis of Breast Cancer

    Recruiting
    • Breast Cancer
      • Nijmegen, Gelderland, Netherlands
      • +1 more
      Jul 11, 2022

      Monocyte Expression of Human Leukocyte Antigen - DR Isotype

      Recruiting
      • Critical Care
      • Blood sampling
      • Lyon, France
        Service de reanimation chirurgicale
      Oct 27, 2022

      Lactulose, Polyethylene Glycol, Bowel Preparation Trial in Montevideo (Lactulose, Polyethylene Glycol 3350)

      Recruiting
      • Lactulose
      • +4 more
      • Montevideo, Uruguay
        Hospital de Clinicas
      Feb 10, 2023

      Cancer Trial in Stockholm (68Ga-NOTA-PEG2-RM26)

      Recruiting
      • Cancer
      • Stockholm, Sweden
        Karolinska University Hospital
      Nov 23, 2023

      Breast Cancer Stage IV Trial in Iowa City, New Delhi, Chandigarh (Lutetium-177-PEG-avß3-IAC)

      Not yet recruiting
      • Breast Cancer Stage IV
      • Iowa City, Iowa
      • +2 more
      Jun 7, 2022

      Immunogenicity of First Doses of PEG-Asparaginase -An

      Recruiting
      • Acute Lymphoblastic Leukemia
        • Aarhus N, Denmark
        • +1 more
        Jan 25, 2023

        Primary Prevention Trial in Aurora (Boot Camp Translation, Control)

        Recruiting
        • Primary Prevention
        • Boot Camp Translation
        • Control
        • Aurora, Colorado
          University of Colorado Hospital
        Jan 24, 2023

        Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic Trial in Guangzhou (Chidamide, Dasatinib)

        Recruiting
        • Leukemia
        • +3 more
        • Guangzhou, Guangdong, China
          Department of Hematology, Nanfang Hospital
        Jun 28, 2022